ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,761.00
0.77%
S&P ASX All Technology
3,066.90
-0.26%
Brent Oil
78.445
-2.92%
US Dollar vs AUD
1.49611
-0.16%
Bitcoin
69,254.32
2.22%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Legend Biotech Corporation (LEGN)

  7. Legend Biotech Corporation (LEGN) News

LEGN

Legend Biotech (LEGN)

Legend Biotech Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LEGN
DateTimeSourceHeadlineSymbolCompany
29/05/202422:00Business WireLegend Biotech to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
24/05/202407:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
24/05/202407:00Business WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
13/05/202421:10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:LEGNLegend Biotech Corporation
13/05/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
13/05/202421:00Business WireLegend Biotech Reports First Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
23/04/202403:05Business WireCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/04/202422:00Business WireLegend Biotech to Host Investor Conference Call on First Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
06/04/202414:30Business WireLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
19/03/202423:30Business WireLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) ReportNASDAQ:LEGNLegend Biotech Corporation
16/03/202406:15Business WireCARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/03/202422:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
11/03/202422:00Business WireLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
11/03/202421:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:LEGNLegend Biotech Corporation
29/02/202410:46Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LEGNLegend Biotech Corporation
28/02/202411:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
24/02/202405:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
23/02/202423:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
23/02/202423:15Business WireLegend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of TherapyNASDAQ:LEGNLegend Biotech Corporation
15/02/202412:34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEGNLegend Biotech Corporation
14/02/202400:00Business WireLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 ResultsNASDAQ:LEGNLegend Biotech Corporation
24/01/202401:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
23/01/202423:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
10/01/202408:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
04/01/202403:28Business WireLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
04/01/202400:30Business WireLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
03/01/202400:30Business WireLegend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
28/12/202302:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
23/12/202307:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
23/12/202307:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
 Showing the most relevant articles for your search:NASDAQ:LEGN

Your Recent History

AMEX
FNDE
Schwab Fundamental Emerg...
LSE
FJ09
Barclays 25
USOTC
PEYUF
Peyto Exploration and De... (PK)
LATK
SPELLFIREUSDT
SPELLFIRE Token
USOTC
PZZPF
Paz Oil (PK)
LSE
AR46
Citi Fun 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved